Randomized Controlled Study of Dragonfly System for Functional Mitral Regurgitation
Key facts
- Who runs it
- Hangzhou Valgen Medtech Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 148 people, planned
- Started
- 30 Dec 2025
- Expected to end
- 30 Jun 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- DragonFly System
- Drug
- Record updated
- 21 November 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Age ≥ 18 yrs. 2) Symptomatic functional mitral regurgitation (FMR) (≥3+) due to ischemic or non-ischemic cardiomyopathy
- Transseptal catheterization and femoral vein access is determined to be feasible
- The subject or subject's legal representative has been informed of the nature of the trial, willing to accept the experimental tests, and has provided written informed consent
Who cannot take part
- Currently participating in an investigational drug or another device study that has not completed its primary endpoints or would clinically interfere with the endpoint of this study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials
- The presence of other severe heart valve disease requiring surgical intervention
- Echocardiographic evidence of intracardiac mass, thrombus, or vegetation. 2)Echocardiography revealed severe restriction of leaflet motion due to tethering
- In the judgment of the investigator, subjects may not complete the trial according to poor compliance or in other circumstances when the investigator determines that the subject is unfit to participate in the study
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Mitral regurgitation functional
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To confirm the effectiveness and safety of the Dragonfly transcatheter mitral valve repair system for the treatment of chronic moderate to severe (3+) or severe (4+) functional mitral regurgitation (FMR) who remained clinically symptomatic after adequate treatment.
The 2 groups in the trial
- Randomized - Device GroupTreatment being tested
This group is allocated to use DragonFly System for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
Treatment: DragonFly System and Drug
- Randomized - Control GroupExisting treatment, for comparison
This group will continue to be managed on medical therapy, per physician discretion
Treatment: DragonFly System and Drug
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter, Randomized Controlled Clinical Study to Evaluate the Safety and Effectiveness of the DragonFly Transcatheter Mitral Valve Clip System in the Treatment of Moderate-to-Severe or Severe Functional Mitral Regurgitation (FMR)
- Criteria questions
- Built from NCT07243158, who can take part
- Record updated
- 21 November 2025